U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda ’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

Osaka, JAPAN, December 15, 2020– Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for review the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news